

Samumed

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.

Overview:

Geographic Region: U.S.

Industry: Biotechnology

Company Website: www.samumed.com

CEO: Osman Kibar

Investors:

IKEA GreenTech

The Pfizer Incubator

Vickers Venture Partners

Starling Group

Latest Funding Round

Date	Transaction Type	Lead Investor	Number of Investors	Capital Raised	Valuation
08/06/2018	Series A	Starling Group, Vickers Venture Partners	2	\$438M	\$12B